Volume 77, Issue 4, Pages (February 2010)

Slides:



Advertisements
Similar presentations
Melamine toxicity: one more culprit in calcium kidney lithiasis
Advertisements

Moss-made Biopharmaceuticals
Viper venom for diabetic nephropathy
Glomerular Diseases Dependent on Complement Activation, Including Atypical Hemolytic Uremic Syndrome, Membranoproliferative Glomerulonephritis, and C3.
Sanjeev Sethi, Carla M. Nester, Richard J.H. Smith 
Takehiko Wada, Masaomi Nangaku  Kidney International 
Discontinuation of Eculizumab in a Patient With Atypical Hemolytic Uremic Syndrome Due to a Mutation in CFH  Sandra Habbig, MD, Carsten Bergmann, MD,
Shining light on vitamin D trials in chronic kidney disease
Viper venom for diabetic nephropathy
Mechanisms of myocardial reperfusion injury
Continuous renal replacement therapy in the critically ill patient
Status of chronic kidney disease prevention programs: International Federation of Kidney Foundation Members 2005/2007  Joanna M. Smith, Susan A. Mott,
E. Goicoechea de Jorge, Matthew C. Pickering  Kidney International 
Complement in Kidney Disease: Core Curriculum 2015
Volume 58, Issue 1, Pages (July 2000)
Volume 85, Issue 3, Pages (March 2014)
Volume 80, Issue 4, Pages (August 2011)
Comorbidity and confounding in end-stage renal disease
Volume 74, Issue 3, Pages (August 2008)
Volume 73, Issue 4, Pages (February 2008)
Volume 73, Issue 7, Pages (April 2008)
Volume 87, Issue 2, Pages (February 2015)
The molecular biology of thrombotic microangiopathy
Complement in Kidney Disease: Core Curriculum 2015
Pieter Evenepoel, Björn K. Meijers  Kidney International 
Volume 74, Issue 3, Pages (August 2008)
Melamine toxicity: one more culprit in calcium kidney lithiasis
Volume 73, Issue 12, Pages (June 2008)
A physician's perseverance uncovers problems in a key nephrology study
The third World Kidney Day: Looking back and thinking forward
Extracorporeal therapy in sepsis: are we there yet?
Volume 69, Issue 12, Pages (June 2006)
Volume 69, Issue 3, Pages (February 2006)
Kidney failure and the gut: p-cresol and the dangers from within
Volume 74, Issue 8, Pages (October 2008)
Alternate-day dialysis may be needed for hemodialysis patients
Nephrology Crossword: Peritoneal Dialysis
Calcium sensing in podocytes
Iron-refractory iron deficiency anemia: new molecular mechanisms
Atrial fibrillation in end-stage renal disease: an emerging problem
Volume 56, Issue 4, Pages (October 1999)
Starting dialysis is dangerous: how do we balance the risk?
Nephrology Crossword: Glomerulonephritis
A practical approach to the treatment of depression in patients with chronic kidney disease and end-stage renal disease  S. Susan Hedayati, Venkata Yalamanchili,
Volume 71, Issue 4, Pages (February 2007)
The riddle of the sphinx redux
Douglas G Matsell, Colin T White  Kidney International 
Fibroblast growth factor 23: the making of a hormone
A possible mechanism of renal cell death after ischemia/reperfusion
It's not over till the last glomerulus forms
Volume 82, Issue 9, Pages (November 2012)
The molecular biology of thrombotic microangiopathy
Immunity unmasks APOL1 in collapsing glomerulopathy
Volume 80, Issue 10, Pages (November 2011)
Volume 80, Issue 10, Pages (November 2011)
Volume 73, Issue 8, Pages (April 2008)
Is it the low-protein diet or simply the salt restriction?
Immunoregulatory role of TNFα in inflammatory kidney diseases
Is complement a target for therapy in renal disease?
Volume 70, Issue 3, Pages (August 2006)
Renal prognosis of toxigenic Escherichia coli infection
Tobias Breidthardt, Alexandre Mebazaa, Christian E. Mueller 
Volume 75, Issue 7, Pages (April 2009)
The changing face of childhood nephrotic syndrome
Aldosterone and potassium secretion by the cortical collecting duct
T cells and T-cell receptors in acute renal failure
The international realities of live donor kidney transplantation
Novel aspects of complement in kidney injury
Abby S. Kazley, Kit N. Simpson, Kenneth D. Chavin, Prabhakar Baliga 
Volume 75, Issue 8, Pages (April 2009)
Presentation transcript:

Volume 77, Issue 4, Pages 267-269 (February 2010) Excessive activation of the complement system in atypical hemolytic uremic syndrome: is it ready for prime time?  Han-Mou Tsai  Kidney International  Volume 77, Issue 4, Pages 267-269 (February 2010) DOI: 10.1038/ki.2009.467 Copyright © 2010 International Society of Nephrology Terms and Conditions

Figure 1 Deficiency of complement factor H-related protein 1 aggravates the atypical hemolytic uremic syndrome in patients with complement factor I (CFI) mutations. This scheme depicts the roles of complement factor H (CFH), CFI, and CFH-related protein 1 (CFHR-1) in regulating the activation of the alternative complement pathway and the formation of the terminal complement complex C5b-9. Because activation of the alternative pathway is spontaneous, regulators are particularly critical for preventing its excessive activation. CFH, by binding to C3b, promotes the cleavage of the latter by CFI to iC3b. In addition, CFH also prevents the association of C3b with factor B, thereby preventing the formation of C3 convertase (C3bBb) and C5 convertase (C3bBbC3b). CFHR-1 binds to C5, inhibiting its activation by C5 convertase and the formation of the terminal complement complex (C5b-9). This scheme explains why, compared with CFH deficiency, CFI deficiency is a weak cause of atypical hemolytic uremic syndrome (aHUS). It also explains why CFHR-1 deficiency does not cause aHUS but markedly worsens aHUS in association with CFI deficiency. Other complement pathways, regulators, and receptors are not shown in this simplified scheme. Kidney International 2010 77, 267-269DOI: (10.1038/ki.2009.467) Copyright © 2010 International Society of Nephrology Terms and Conditions